[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489126":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":60,"id":63,"slug":30,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":30,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":43,"whyStopped":30,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Massachusetts Institute of Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cannabidiol","ACTIVE_COMPARATOR","300mg Cannabidiol (3mL Epidiolex), oral, single-dose",[13],"Drug: Cannabidiol",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo (3mL sesame seed oil), oral, single-dose",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol\u002FmL) in a single-dose.",[9],[26],"Epidiolex",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.",[15],null,[32],{"name":33,"affiliation":5,"role":34},"John Gabrieli, PhD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Omar Rutledge, MS","CONTACT","617-324-2898","orutledge@mit.edu",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Cambridge","Massachusetts","02139","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-71.10561,42.3751,{"lat":53,"lon":52},[56,57],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":33,"role":34,"phone":30,"phoneExt":30,"email":30},{"type":59,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[61],{"name":62,"class":6},"Massachusetts General Hospital","100489126",false,"NCT05649059","Investigating the Effects of Cannabidiol on Social Anxiety Disorder","CAN-SAD","Inclusion Criteria:\n\n* Ability and willingness to provide written informed consent.\n* Sufficiently fluent in English to participate in the trial.\n* Between 18-55 years of age (inclusive).\n* Right-hand dominant.\n* Current medications are stable for past 30 days (no changes to dose or frequency).\n* Negative result on pregnancy test (if female).\n* Negative result on urine drug screening.\n* Liebowitz Social Anxiety Scale (LSAS ≥ 60).\n\nExclusion Criteria:\n\n* History of bipolar disorder, schizophrenia, psychosis, delusional disorders.\n* History of eating disorder within past 6 months.\n* History of any traumatic brain injury.\n* Currently diagnosed with diabetes mellitus.\n* Presence of severe medical illness that would prevent completion of study procedures.\n* Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia).\n* History of substance use disorder within past 6 months (other than nicotine and caffeine).\n* Use of any cannabis-containing products in past 30 days (CBD or THC).\n* Use of benzodiazepines in past 2 weeks.\n* Use of alpha- or beta-blockers in past week.\n* History of claustrophobia.\n* Contraindications for MRI (e.g.; shrapnel).\n* Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures.\n* Use of concomitant medication that has a strong interaction with CBD.\n* History of liver disease.\n* History of hypersensitivity to cannabinoids.\n* History of hypersensitivity to sesame seed oil.\n* Currently breastfeeding (if female).","ALL","18 Years","55 Years",{"count":73,"type":74},50,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).",[80],"Phobia, Social",[82,9,83],"Social Anxiety Disorder","fMRI","2025-11-25",{"date":86,"type":87},"2025-12-03","ACTUAL",{"date":89,"type":87},"2025-07-10",{"date":91,"type":74},"2026-09",{"name":5,"class":6},1]